Diploma PLC (LON:DPLM – Get Free Report) has earned a consensus rating of “Moderate Buy” from the eight ratings firms that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is GBX 7,400.
A number of equities analysts have weighed in on the stock. Berenberg Bank reissued a “buy” rating and issued a GBX 9,000 price objective on shares of Diploma in a research report on Monday, July 20th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a GBX 7,400 target price on shares of Diploma in a research report on Tuesday, September 8th. Jefferies Financial Group reaffirmed a “hold” rating and set a GBX 7,000 target price on shares of Diploma in a research report on Friday, May 29th. Finally, JPMorgan Chase & Co. boosted their price target on Diploma from GBX 5,760 to GBX 8,250 and gave the stock an “overweight” rating in a research note on Monday, August 24th.
View Our Latest Stock Analysis on Diploma
Diploma Price Performance
Insiders Place Their Bets
In other Diploma news, insider Mandy Gradden bought 1,000 shares of the business’s stock in a transaction on Friday, July 17th. The shares were bought at an average cost of GBX 7,183 per share, with a total value of £71,830. Also, insider Katie Bickerstaffe bought 47 shares of Diploma stock in a transaction dated Thursday, July 16th. The shares were acquired at an average price of GBX 7,050 per share, with a total value of £3,313.50. Insiders have acquired 1,604 shares of company stock worth $11,447,718 in the last three months. 1.14% of the stock is owned by insiders.
Diploma Company Profile
Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.
Featured Stories
- Five stocks we like better than Diploma
- Aeluma’s Selloff Could Be Setting Up Its Next Big Move
- Crypto Bill Stalls, Smart Money Calls: Time to Buy the Dip?
- The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks
- The Fed’s Rate Hike Could Backfire If Oil Prices Collapse
Receive News & Ratings for Diploma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diploma and related companies with MarketBeat.com's FREE daily email newsletter.
